Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
F. Ortiz-Sanjuán¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, A Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, Elena Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, J García³⁸, AJ García González³⁹, Raquel Almodovar⁴⁰, E Minguez⁴¹, C Carrasco Cubero⁴², Alejandro Olivé Marqués⁴³, J Vázquez⁴⁴, O Ruiz Moreno⁴⁵, F Jimenez-Zorzo⁴⁵, J Manero⁴⁵, Javier Loricera² and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Baracaldo, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles. Madrid, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology, Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴¹Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴³Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴⁴Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁵Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…
Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting
Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Akihiko Nakabayashi¹, Toru Hirano², Yoshihiro Hishitani², Keisuke Hagihara³, Kei Nakai⁴, Kouji Nishida⁴ and Atsushi Kumanogoh², ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ⁴Department of Ophthalmology, Osaka University Graduate School of Medicine, suita, Japan
Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…
Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Fatma Alibaz-Oner¹, Gonca Mumcu², Zeynep Kubilay³, Gülsen Ozen⁴, Gülce Celik³, Aslı Karadeniz³, Meryem Can⁵, Sibel Yılmaz Oner¹, Nevsun Inanc⁶, Pamir Atagunduz⁷, Tülin Ergun⁸ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, ⁵Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Marmara University School of Medicine, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁸Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…
Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting
Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Caner Saygin¹, Didem Uzunaslan¹, Gulen Hatemi², Koray Tascilar¹ and Hasan Yazici³, ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…
Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Nicolas Noel¹, Remy Bernard², Bertrand Wechsler³, Matthieu Resche-Rigon², Du Boutin⁴, Jean-Charles Piette⁵, Aurélie Drier⁶, Didier Dormont⁶, Patrice Cacoub⁴ and David Saadoun⁷, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Internal Medecine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁶Neuroradiology, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…
Abstract Number: 2613 • 2013 ACR/ARHP Annual Meeting
NF-κB Pathway Is Depleted In Phagocytes From Behçet´s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W.S. Souza^4,5, Antonio Condino-Neto³ and Luis Eduardo C. Andrade⁶, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: : Increased neutrophil activation has been previously shown in Behçet’s disease (BD) patients and it is unclear whether neutrophil activation occurs constitutively or if…
Abstract Number: 1905 • 2013 ACR/ARHP Annual Meeting
Protein Profiles Of Peripheral Blood Mononuclear Cells As a Biomarker For Behcet’s Disease
Manae Kurokawa¹, Takuya Yoshioka², Toshiyuki Sato¹, Kouhei Nagai¹, Nobuko Iizuka¹, Mitsumi Arito¹, Yukiko Takakuwa², Hiromasa Nakano², Seido Ooka², Naoya Suematsu¹, Kazuki Okamoto¹, HIroshi Nakamura³, Noboru Suzuki⁴, Shoichi Ozaki⁵ and Tomohiro Kato¹, ¹Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Department of Rheumatology, Nippon Medical School, Bunkyo-ku, Japan, ⁴Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: To investigate the pathophysiology of Behcet’s disease (BD) and find biomarker candidates for the disease, we analyzed protein profiles of peripheral blood mononuclear cells…
Abstract Number: 2616 • 2013 ACR/ARHP Annual Meeting
Ischemia-Modified Albumin : A Novel Marker of Vascular Involvement in Behcet’s Disease ?
Erhan Capkin¹, Murat Karkucak², Mehmet Kola³, Adem Karaca², süleyman Caner Karahan⁴, Aysegul Sumer⁴, Arzu Aydin Capkin⁵, Ferhat Gokmen² and Refik Ali Sari⁶, ¹rheumatolgy, trabzon, Turkey, ²rheumatology, trabzon, Turkey, ³oftalmology, trabzon, Turkey, ⁴biochemistry, trabzon, Turkey, ⁵dermatology, trabzon, Turkey, ⁶immunology and allergy, trabzon, Turkey
Background/Purpose: The etiology and pathogenesis of Behçet’s disease (BD) are not yet well understood, but immunoregulatory abnormalities have been proposed as pathogenic mechanisms. Ischemia-modified albumin…
Abstract Number: 1879 • 2013 ACR/ARHP Annual Meeting
Major Histocompatibility Complex Class I Molecules Contribute To Behçet’s Disease Risk Through Both Innate and Adaptive Immune Interactions
Michael J. Ombrello^1,2, Yohei Kirino^2,3, Paul de Bakker⁴, Ahmet Gül⁵, Elaine F. Remmers⁶ and Daniel L. Kastner⁷, ¹Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁷Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Behçet's Disease (BD) is a complex genetic disease of unknown etiology that is characterized by inflammatory lesions of the eyes, skin, and oro-genital mucosa.…
Abstract Number: 2618 • 2013 ACR/ARHP Annual Meeting
Bipolar Disorders May Represent a Primary Feature Of Behçet’s Disease
Rosaria Talarico¹, Laura Palagini², Elena Elefante³, Claudia Ferrari⁴, Chiara Stagnaro³, Chiara Baldini³, Chiari Tani³, Marta Mosca⁴ and Stefano Bombardieri³, ¹Rheumatology Unit, Pisa, Italy, ²University of Pisa, Psychiatry Unit, Department of Neuroscience, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Frequency of psychiatric disorders in BD is a debated issue: while some experts attribute their presence to the chronicity of the illness, others think…
Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Francisco Ortiz-Sanjuan¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, Agustí Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, E. Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, AJ García González³⁸, Raquel Almodovar³⁹, E Minguez⁴⁰, C Carrasco Cubero⁴¹, Alejandro Olive Marques⁴², J Vázquez⁴³, O Ruiz Moreno⁴⁴, F Jimenez-Zorzo⁴⁴, J Manero⁴⁴, Javier Loricera¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴⁰Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴¹Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴²Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴³Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁴Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
Abstract Number: 2619 • 2013 ACR/ARHP Annual Meeting
Suicidal Ideation Among Patients With Behcet’s Syndrome
Didem Uzunaslan¹, Caner Saygin¹, Gulen Hatemi², Koray Tascilar¹, Hasan Yazici³ and Vedat Hamuryudan⁴, ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁴Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: An increased frequency of depression has been reported in Behcet’s syndrome (BS). While an increased suicidal ideation has been reported in other chronic rheumatologic conditions, this…
Abstract Number: 1751 • 2013 ACR/ARHP Annual Meeting
Ethnicity-Related Differences In Behçet’s Disease In a French Multiethnic Country
David Saadoun¹, Mathieu Resche Rigon², Bertrand Wechsler³, Du Le Thi Huong⁴, Jean-Charles Piette¹ and Patrice Cacoub⁵, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: It has been suggested that Behçet’s disease (BD) varies in its phenotypic expression in different ethnies and in different countries indicating that both environmental…
Abstract Number: 2620 • 2013 ACR/ARHP Annual Meeting
Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease
Claudia Ferrari¹, Rosaria Talarico², Chiara Stagnaro³, Anna d'Ascanio⁴, Chiara Tani³, Chiara Baldini³, Marta Mosca¹ and Stefano Bombardieri³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy
Background/Purpose: Behçet’s disease (BD) is globally characterized by a variable spectrum of disease profile: while prevalent muco-cutaneous lesions and arthritis represent the only clinical features…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].